← Browse by Condition
Medical Condition

iga vasculitis

Total Trials
3
Recruiting Now
3
Trial Phases
Phase 2, Phase 3

ClinicalMetric tracks all active clinical trials for iga vasculitis sourced from ClinicalTrials.gov. Research in this area spans early-phase safety investigations through large Phase 3 confirmatory trials, conducted by NIH-funded academic centers, independent investigators, and pharmaceutical sponsors worldwide. Each listing is updated daily as new studies open enrollment and existing ones reach capacity or complete follow-up.

Trial listings include the NCT identifier, current recruitment status, phase classification, primary and secondary endpoints, estimated enrollment size, participating countries, and direct links to the full protocol on ClinicalTrials.gov. Eligibility criteria — including age range, disease stage, and prior treatment requirements — are documented for every study to help patients and clinicians assess suitability before contacting a trial site.

Frequently Asked Questions — iga vasculitis Clinical Trials

How many clinical trials are currently recruiting for iga vasculitis?
ClinicalMetric currently tracks 3 actively recruiting clinical trials for iga vasculitis, sourced in real time from ClinicalTrials.gov. The total number of registered studies—including those not yet enrolling or in active follow-up—is 3. Trial availability changes daily as new studies open enrollment and existing ones reach capacity.
What trial phases are available for iga vasculitis?
iga vasculitis research spans Phase 2 (1 trial), Phase 3 (1 trial). Phase 1 studies evaluate safety and dosing in small groups, Phase 2 studies assess preliminary efficacy in 100–300 participants, and Phase 3 trials compare the new treatment against the standard of care in 300–3,000+ patients. Phase 4 post-approval studies monitor long-term outcomes in real-world populations.
How do I find out if I qualify for a iga vasculitis clinical trial?
Eligibility criteria for iga vasculitis trials vary by study and typically specify age range, disease stage or severity, prior treatment history, and specific diagnostic or laboratory parameters. Each listing on ClinicalMetric links to the full protocol on ClinicalTrials.gov, where inclusion and exclusion criteria are documented. Contact the sponsoring site's research coordinator directly to confirm your eligibility—your treating physician or specialist can also help identify the most appropriate trial based on your medical history and current treatment status.
Trial Phases
Phase 2
1
Phase 3
1
Top Sponsors
University of Pennsylvania 1 trial
Alexion Pharmaceuticals, Inc. 1 trial
Peter Merkel 1 trial

Recruiting Clinical Trials

NCT02939573 Phase 2
Recruiting
A Randomized Multicenter Study for Isolated Skin Vasculitis
Enrollment
90 pts
Location
United States, Canad...
Sponsor
University of Pennsylvania
View Trial →
NCT07024563 Phase 3
Recruiting
Study of Ravulizumab in Pediatric Participants With Primary IgAN
Enrollment
24 pts
Location
United States, China...
Sponsor
Alexion Pharmaceuticals, Inc.
View Trial →
NCT03004326
Recruiting
Clinical Transcriptomics in Systemic Vasculitis (CUTIS)
Enrollment
50 pts
Location
United States, Canad...
Sponsor
Peter Merkel
View Trial →

Related Conditions

primary cutaneous vasculitis (1) cutaneous polyarteritis nodosa (1) henoch sch nlein purpura (1) igan (1) igavn (1) immunoglobulin a nephropathy (1) immunoglobulin a vasculitis associated nephritis (1) henoch schonlein purpura nephritis (1) cryoglobulinemic vasculitis cv (1) drug induced vasculitis (1) eosinophilic granulomatosis with polyangiitis egpa (1) isolated cutaneous vasculitis (1)
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology